NCTId,OrgStudyId,Acronym,BriefTitle,OfficialTitle,OverallStatus,LastKnownStatus,WhyStopped,ExpandedAccessStatus,StartDate,PrimaryCompletionDate,CompletionDate,StartDateType,Phase,StudyType,DesignAllocation,DesignInterventionModel,DesignPrimaryPurpose,DesignMasking,NumberOfArms,Condition,OtherKeywords,InterventionName,InterventionType,InterventionDescription,ArmName,ArmDescription,LeadSponsorName,ResponsiblePartyName,CollaboratorName,EnrollmentCount,EnrollmentType,Gender,MinimumAge,MaximumAge,HealthyVolunteers,EligibilityCriteria,BriefSummary,DetailedDescription,PrimaryOutcomeMeasure,PrimaryOutcomeTimeFrame,SecondaryOutcomeMeasure,SecondaryOutcomeTimeFrame,LocationFacility,LocationCity,LocationState,LocationZip,LocationCountry,OverallContactName,OverallContactPhone,OverallContactEmail,ReferenceCitation,DocumentDate,DocumentType
NCT06272487,,KARDIA-3,Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3),"A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Zilebesiran Used as Add-on Therapy in Adult Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications",ACTIVE_NOT_RECRUITING,,,,2024-02-29,2025-04-02,2025-12-19,ACTUAL,PHASE2,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,,High Cardiovascular Risk; Hypertension,High blood pressure; Hypertension; siRNA; Angiotensinogen; AGT; Cardiovascular disease; Chronic kidney disease; Uncontrolled hypertension,Zilebesiran; Placebo,DRUG; DRUG,Zilebesiran administered by subcutaneous (SC) injection; Placebo administered by SC injection,,,,,,,,,18 Years,,False,,The purpose of this study is to evaluate the effect of zilebesiran as add-on therapy in patients with high cardiovascular risk and hypertension not adequately controlled by standard of care antihypertensive medications.,,,,,,,,,,,,,,,,
NCT06423352,,,A Study to Evaluate Zilebesiran in Japanese Patients With Mild to Moderate Hypertension,"A Phase 1/2, Randomized, Double-blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacodynamics, and Pharmacokinetics of Zilebesiran in Japanese Patients With Mild to Moderate Hypertension",COMPLETED,,,,2024-06-05,2025-07-17,2025-07-17,ACTUAL,PHASE1; PHASE2,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,TRIPLE,,Mild to Moderate Hypertension,High blood pressure; Hypertension; Hypertensive; siRNA; Angiotensinogen; AGT,Zilebesiran; Placebo,DRUG; DRUG,Zilebesiran administered by subcutaneous (SC) injection; Placebo administered by SC injection,,,,,,,,,18 Years,75 Years,False,,"The purpose of this study is to evaluate the safety, tolerability, efficacy, pharmacodynamics (PD) and pharmacokinetics (PK) of zilebesiran in Japanese patients with mild to moderate hypertension.",,,,,,,,,,,,,,,,
NCT03934307,,,A Study to Evaluate ALN-AGT01 in Patients With Hypertension,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled Single Dose and Active Comparator-Controlled Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered ALN-AGT01 in Patients With Hypertension",COMPLETED,,,,2019-05-01,2022-04-20,2023-01-04,ACTUAL,PHASE1,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,,Hypertension,,ALN-AGT01; ALN-AGT01-Matching Placebo; Irbesartan; Irbesartan-Matching Placebo,DRUG; DRUG; DRUG; DRUG,ALN-AGT01 will be administered by subcutaneous (SC) injection.; Normal saline (0.9% NaCl) matching volume of ALN-AGT01 doses will be administered SC.; Irbesartan will be administered orally.; Irbesartan-matching placebo will be administered orally.,,,,,,,,,18 Years,65 Years,False,,"The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) effects of subcutaneous (SC) ALN-AGT01 (zilebesiran) in participants with hypertension. The study will be conducted in 4 parts: Part A will be a single ascending dose (SAD) phase in hypertensive participants, Part B will be a single dose (SD) phase in hypertensive participants with controlled salt intake, Part D will be a MD phase in hypertensive participants who are obese, and Part E will be an open-label SD phase with co-administration of irbesartan in hypertensive patients.",,,,,,,,,,,,,,,,
NCT04936035,,KARDIA-1,A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension,"A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension",COMPLETED,,,,2021-07-07,2023-04-04,2024-12-05,ACTUAL,PHASE2,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,,Hypertension,High blood pressure; Hypertension; Hypertensive; siRNA; Angiotensinogen; AGT,Placebo; ALN-AGT01,DRUG; DRUG,Placebo administered by SC injection; ALN-AGT01 administered by SC injection,,,,,,,,,18 Years,75 Years,False,,The purpose of this study is to evaluate the effect of ALN-AGT01 on systolic and diastolic blood pressure and to characterize the pharmacodynamic (PD) effects and safety of ALN-AGT01.,Participants will receive ALN-AGT01 or placebo for the first 6 months of the 12-month double-blind (DB) treatment period. Participants randomized to placebo will be re-randomized at Month 6 to 1 of the 4 initial ALN-AGT01 regimens until the end of the 12-month DB treatment period. Participants randomized to ALN-AGT01 regimens will remain on their originally assigned regimens through remainder of the study.,,,,,,,,,,,,,,,
NCT05103332,,KARDIA-2,Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2),"A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Zilebesiran Used as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication",COMPLETED,,,,2021-11-05,2023-12-11,2024-09-13,ACTUAL,PHASE2,INTERVENTIONAL,RANDOMIZED,PARALLEL,TREATMENT,QUADRUPLE,,Hypertension,High blood pressure; Hypertension; Hypertensive; siRNA; Angiotensinogen; AGT,Indapamide; Amlodipine; Olmesartan; Placebo; Zilebesiran,DRUG; DRUG; DRUG; DRUG; DRUG,Indapamide administered orally; Amlodipine administered orally; Olmesartan administered orally; Placebo administered by SC injection; Zilebesiran administered by SC injection,,,,,,,,,18 Years,75 Years,False,,The purpose of this study is to evaluate the effect of zilebesiran on systolic and diastolic blood pressure and to characterize the pharmacodynamic (PD) effects and safety of zilebesiran as add-on therapy.,,,,,,,,,,,,,,,,
